Dear Editor:
The article "Psychiatric and Neuropsychiatric Manifestations of HIV Infection" by Dr. Ewald Horwath in the November 2002 supplement of the Journal of the International Association of Physicians in AIDS Care (JIAPAC) addressed a very important topic. The scope of such an article is large and thus the degree of depth is necessarily limited; the balance between scope and depth is generally achieved. Yet there is selective presentation of data and an unbalanced review of treatment.
The potential neuropsychiatric side effects of efavirenz are relatively overemphasized, presented with an uncritical use of data. For example, the section that discusses cerebrospinal fluid (CSF) penetration has no source cited and lists the penetration for efavirenz inaccurately. According to a study presented by Karen Tashima in 1998, the penetration is 10-fold higher than the IC 95 for wild type virus, and according to the drug's package insert, the actual penetration ranges from .26 to 1.19 with a mean of .69 percent. 1, 2 In contrast, the author neglects to mention any central nervous system (CNS) side effects for nevirapine, despite two recent studies from the British Medical Journal that suggest a link between nevirapine and hallucinations, depression, and vivid dreams. 3 A recent study in AIDS suggests CNS side effects are nonnucleoside reverse transcriptase inhibitor (NNRTI)-class related and less specific to efavirenz. 4 The review of the International Association of Physicians in AIDS Care (IAPAC) physician survey leads to potentially spurious conclusions. More information about two areas, patient selection and side-effect management, might greatly alter treatment patterns and recommendations. While little is known about patient risk factors for neuropsychiatric side effects, much is known about their management. Key points about management are the basic treatment of uncomplicated depression, anxiety, agitation, and insomnia with use of antidepressants (selective serotonin reuptake inhibitors (SSRIs) preferentially over tricyclic antidepressants (TCAs)), sedative-hypnotics, and mood stabilizers (including some atypical neuroleptics). 5 A brief discussion of treatment would include clinically relevant potential drugdrug interactions and thus note the generally regarded safety and efficacy of treating medication-induced depression (whether from NNRTIs or interferon (IFN), for example) with SSRIs.
Access to appropriate and effective side-effect and symptom management is an essential component of HIV treatment. As is consistent with clinical experience, CNS side-effect management significantly and cost-effectively enhances adherence by targeting several important barriers to adherence. 6, 7 Accurate and balanced responsible reviews are essential to the further education of treatment providers and to the improvement in HIV/AIDS care. I appreciate the opportunity to reply to the points raised by Dr. David Goldenberg. I thank him for acknowledging the large scope of the article, and that the need to provide an overview precluded the possibility of an exhaustive review of each subject area. However, I disagree with his unwarranted assertion that the neuropsychiatric side effects of efavirenz were overemphasized. Numerous publications have documented the frequent and sometimes serious central nervous system (CNS) side effects seen with efavirenz. The Dupont 006 study reported that 55 percent of subjects experienced CNS side effects. 1 Most of these occurred in the first month of treatment, were transient, and were of mild-to-moderate severity. More recently, a multicenter prospective study in 1,033 HIV-infected patients found CNS disturbances that were considered related to efavirenz in 18.5 percent of patients. 2 Most of these were not severe, but treatment had to be interrupted in 6 percent of patients.
In 2003, Lochet et al, reported that, although neuropsychiatric adverse reactions occur mainly during the first month of efavirenz therapy, they often persist thereafter. 3 In Lochet's study, late emergent neuropsychiatric adverse reactions included abnormal dreams (24.7 percent), nocturnal waking (19.6 percent), trouble falling asleep (17.8 percent), memory disorders (23 percent), impaired concentration (18.9 percent), and suicidal ideation (9.2 percent).
The precise incidence, persistence, and severity of CNS side effects related to efavirenz may vary among different populations. The role of risk factors such as prior psychiatric disorder, substance abuse, and other CNS disturbances is not fully understood. However, the authors of several studies have recommended close follow-up and monitoring for psychiatric adverse effects in patients treated with efavirenz, 3, 4 especially in those with prior histories of psychiatric disorder. 5 According to a report by Zaccarelli et al, 6 patients who took efavirenz and experienced CNS side effects had a four-fold increased hazard ratio for virologic rebound and treatment failure, when compared to those without CNS side effects. Clearly, efavirenz-associated CNS symptoms require attention and appropriate management.
I'm puzzled as to why Dr. Goldenberg emphasizes the CNS side effects of nevirapine. He cites two British Medical Journal studies, but his reference is for one report of three cases. 7 He cites a study reported in AIDS, in which the authors raise the question of whether neuropsychiatric complications are a non-nucleoside reverse transcriptase inhibitor (NNRTI)-class effect based upon a report of four cases of vivid dreams attributed to nevirapine. 8 This may be an interesting question, but four case reports hardly constitute solid evidence for a class effect, particularly when balanced against the broad body of literature documenting CNS side effects due to efavirenz. The literature on nevirapine has documented adverse reactions, such as rashes and hepatotoxicity, but psychiatric side effects have not been a significant problem. At the 10th Conference on Retroviruses and Opportunistic Infections (CROI) in February 2003, a report from the 2NN study, a recent prospective, head-to-head comparison of efavirenz and nevirapine, showed that 5.5 percent of patients taking efavirenz alone experienced Grade 3 or 4 adverse CNS reactions, while 1.4 percent of those taking nevirapine once daily, and 3.6 percent of those taking nevirapine twice daily experienced such symptoms. 9 With regard to CNS penetration, the data on cerebrospinal fluid (CSF)/plasma ratios of antiretrovirals appear to have a very broad range. Tashima's study of 10 patients taking efavirenz, which Dr. Goldenberg cites, reported a range of 0.26 to 0.99 for CSF/plasma ratio. 10 A study by Antinori, reported at the 9th CROI, found undetectable efavirenz levels in the CSF of 11 patients, and a median CSF/plasma ratio of 0.63 for nevirapine, with a range of 0.41 to 0.77. 11 As Dr. Goldenberg suggests, levels such as those reported for efavirenz and nevirapine in the CNS may well be sufficient to suppress viral replication. However, this is a question that remains to be answered empirically, and more direct evidence on the effect of currently used highly active antiretroviral therapy (HAART) regimens on CSF viral load is needed. This issue requires further study.
Dr. Goldenberg calls for discussion of psychiatric symptom management. My review touched on the psychopharmacologic management of early HIV-associated dementia, depression, and psychotic disorders. A broader and more in-depth review of treatment would require another fairly extensive article in order to do the subject justice.
